{"name":"International AIDS Vaccine Initiative","slug":"international-aids-vaccine-initiative","ticker":"","exchange":"","domain":"","description":"The International AIDS Vaccine Initiative (IAVI) is a global not-for-profit, public-private partnership working to accelerate the development of vaccines to prevent HIV infection and AIDS. IAVI researches and develops vaccine candidates, conducts policy analyses, serves as an advocate for the HIV prevention field and engages communities in the trial process and AIDS vaccine education. The organization takes a comprehensive approach to HIV and AIDS that supports existing HIV prevention and treatment programs while emphasizing the need for new AIDS prevention tools. It also works to ensure that future vaccines will be accessible to all who need them.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"TBC-M4","genericName":"TBC-M4","slug":"tbc-m4","indication":"Other","status":"phase_1"},{"name":"mRNA-1645-eODGT8","genericName":"mRNA-1645-eODGT8","slug":"mrna-1645-eodgt8","indication":"Other","status":"phase_1"},{"name":"BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted","genericName":"BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted","slug":"bg505-sosip-gt1-1-gp140-vaccine-adjuvanted","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MTBVAC","genericName":"MTBVAC","slug":"mtbvac","indication":"Tuberculosis prevention in adolescents and adults (Phase 3)","status":"phase_3"}]}],"pipeline":[{"name":"MTBVAC","genericName":"MTBVAC","slug":"mtbvac","phase":"phase_3","mechanism":"MTBVAC is a live attenuated tuberculosis vaccine that stimulates immune responses against Mycobacterium tuberculosis to prevent active TB disease.","indications":["Tuberculosis prevention in adolescents and adults (Phase 3)"],"catalyst":""},{"name":"TBC-M4","genericName":"TBC-M4","slug":"tbc-m4","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"mRNA-1645-eODGT8","genericName":"mRNA-1645-eODGT8","slug":"mrna-1645-eodgt8","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted","genericName":"BG505 SOSIP GT1.1 gp140 Vaccine, Adjuvanted","slug":"bg505-sosip-gt1-1-gp140-vaccine-adjuvanted","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQTGwwaXNiRzl0aTA0emtSVWlKWVo4dEQyR0s4aWlsdEl2SDdjeDZYTXRzMXFrenFBN09nbzQ5WHVyRWQ5bWhKOUVkbUpSMVVBLXhaWmd1WVkyYmswbG1lRjNSX2tkSXRUdTJnZDdLYm9vSC1yOXpmb1hnYlc0NExuek91Y0ttdE1Xc0VJbnlDdmFkajBVRXpPOFptSUpvelhBWFpsV1hBbzVHSzNoSEhBcDhzLUZGY1BMYVp1aTNiUHVxMEU?oc=5","date":"2026-01-19","type":"regulatory","source":"European Pharmaceutical Review","summary":"ReiThera on vaccines and remaining nimble around emerging threats - European Pharmaceutical Review","headline":"ReiThera on vaccines and remaining nimble around emerging threats","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxQbjNGQjc3ZUV4Z3Nyd3BhdW5GdHk3TUdWeWhVWXp1WTZyOW9QSDF3bVBpRG1HaWF2OXkySk5FUnU4dXFzWkptUGp1cnRwRUtWYld0VjJfZmh3S3hvdlZEZXJtRzRpelZManBzdWp2bEhLTkw5MlljQnM0N3cxV1pLcy1CY3hQcFUxTFktTWJtNHdSSTcxeV9LaGdGZmtWSW5jRGJlLUZwMFRIWjJIOUpvSk9MUzJ0VGI2REJmLVp6NkljR05PSVV6c1RLVVBhbS0wQnhFVXVFU1ZnWWFjXzZyMDlBS0VZZm5nbDdCM3VPenE3M1BPQmplZXctVXdORWZ0LUVWd09nTkdYYjVEMmFsTTJzREZ6X3NSYWNpckZLMU52eW11WE9iN3ZfZS1xQTdEcDB0UVIzSnBJdw?oc=5","date":"2025-10-10","type":"pipeline","source":"IAVI","summary":"IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Commercialization, and Access to Vaccines and Antibodies in Africa - IAVI","headline":"IAVI, Minapharm, and ProBioGen Announce Memorandum of Understanding to Progress Clinical Development, Manufacturing, Com","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPX0p1MUtxdlpzV0JodUswQzJKQi1jUHZyN1l0VzZSY09LYlFqd21FbGxuVkFlS1ZVWmJKQ05tLTVMWTkwOUF6UFhQZWRodmx3NVVYRExOS2dyVmxpVkFkaWtSZ0pRa2JYNDJUU1d6Y0NWWmRsVW5oTW1wbU9DZ2NzZUx0dVBjNEE1b1o1NUZ1WFoxMlRZOW8zVHdtQWFubmNKVm4tMHk2SVVKTl9HTjNuaFdXME5QQl9jYzRPa3FCbXBnRjduYWc?oc=5","date":"2025-05-15","type":"trial","source":"IAVI","summary":"Two HIV vaccine trials show proof of concept for pathway to broadly neutralizing antibodies - IAVI","headline":"Two HIV vaccine trials show proof of concept for pathway to broadly neutralizing antibodies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxQM2cxNVFXOFBJQW9QX3NHOVpZSWZsYjAxb1B5clBWMkdDTGJFVnJYd0xkeWJuOHhUTjlpX1p2dUZubl9aV2JpUHJOTTdVTFplUmdkamlnSWFYQXhfVm12LXgya0JXSVNvdU9NNGNFeVcyZktDVXJDLWl2bi00Q2k2OV9hbkIwcGJab0ZIUGpNRDFaa3p4aS1rdTJEdEtjd2JCN3QtYWRaRzhPbGlyTThUT2NHcElnQnJsb0VWcWZSRm1ZaEtIUVZKRW1JQ0haaTJ2Zm5GYXFRWEVkSTY1SVVvYkJWWnRXM2NHcFBxVU5SeXRQLU16Mmh4RUtuNGF1T3VKSmY5WG5DZ29uRndlbDN1LWV0TGxBNWtjQURWMzRHWjlfN0xYVVlYSUw0OA?oc=5","date":"2025-02-26","type":"trial","source":"IAVI","summary":"IAVI and Biofabri/Zendal announce first vaccinations in the IMAGINE clinical trial, a large-scale safety and efficacy trial of the tuberculosis vaccine candidate MTBVAC - IAVI","headline":"IAVI and Biofabri/Zendal announce first vaccinations in the IMAGINE clinical trial, a large-scale safety and efficacy tr","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOZjQ2eE5KRlFhV0I0aE9Ra3cyRWNPSlRtZm9XT0N0NFh5cW1nVlNxTmlPbmRUci1qTmF6SUNmTXQyWkhRRk1GM29kNGpfT005YjJidFpsQWVfX2tFRnNOVzBMTEZLakVRWW1mZkR2bW11enppYVpvbXJBQVdmcG51OXlFQnRSTWlNODNfcE9aUXFPVV9uQzBTMzhCQTNDalI5Z21wbnJuOEZsXzA?oc=5","date":"2023-12-28","type":"pipeline","source":"IAVI","summary":"Six Distinguished Leaders in Global Health Join IAVI Board of Directors - IAVI","headline":"Six Distinguished Leaders in Global Health Join IAVI Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQWk84TGJJYTZ0TWtzR2RuX2dZcWR1cm1oSmxMemJORmY5MXNZbFBFYTZfTkYxVUIzQ1NaVTVyU1d3TnU2YkVzSV96cTNDVnRoam1BZW5SWndWUk5wMGJmckFNWWRPT0xSM2lOQkpwTVNKNkQxMVJDc3ZqTmNsbXJCdml3MW9hQUU3dzc5MkJueVlBVXNSVVNKZnpoWmJyU3JFV2lIQlRnTDNaY3dhanVzSw?oc=5","date":"2023-12-27","type":"pipeline","source":"IAVI","summary":"IAVI’s Fran Priddy Talks Scientific Challenges at AtlanticLIVE’s Vaccines + Immunity - IAVI","headline":"IAVI’s Fran Priddy Talks Scientific Challenges at AtlanticLIVE’s Vaccines + Immunity","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTE54bGdKNXk0TGV3NGhwaFdCcHJSN2Y1eXhwOWtjYXVyeHptekhIVGo2OW8tOEdveUpiTXJfT21MVU5CNk1Qbmo4LWt0Q0tjQlR1bHNla1JoVi1xUUp4eVdfMGoyakFwWlBGYkZkS2syRjBFQjF3d0Jv?oc=5","date":"2023-12-27","type":"pipeline","source":"IAVI","summary":"An industry leader in HIV research - IAVI","headline":"An industry leader in HIV research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxOUWtDdDNBb1JwQ1BYS1ZQRTN1bmxQT2tVaXkyWTh1eDA4WC1HMWxWalpFZGd0U3RZZ21WVVJUZ2xpV3ZwbVUySWtuT1Q1LTFaVW5JMlB2MGEyeTJKY1JlRlF4S1NqS0Nia1lLX0FkVFM0WHpKV3cteGNtc1lxMXZhc1FkZGJZQk93QUZCQnlfOVgtRVY3dFlJMUJ1SXRaZ2Z1V2tPdmZzd3RHT2lGR0pCR3M0VDQ3X2tMb2UtTnNJSU1rNklhYW9RQlNkVnNKb3hvRDVaYnYzVXJub21wZENBSnFuLTFNYy16TlFqbVlrV04zeFZLRUln?oc=5","date":"2023-12-22","type":"regulatory","source":"IAVI","summary":"New IAVI paper makes the case for strengthening clinical and regulatory pathways to accelerate global access to monoclonal antibodies - IAVI","headline":"New IAVI paper makes the case for strengthening clinical and regulatory pathways to accelerate global access to monoclon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOZS14ai1tb1lmVzh5ZEtrMWI2a2ZySDF0ZGJXNFNtYms5T001X2hVLUVFbjF3ZTRfeGR5QlhxV2FnbGVsN1RJWURzYS1QYTN0RWNPZkZxS0ZseHl3VzVjc3EwOW5sS1JGWVBXYmxRZ3pRUmxfbkRQRUJ6eXFEcDU2R2daZFNReTc1YzJuTkRVRkJaNWZrWE1BV0E0SFZqa3NrbURyWjdMVTBBemdCSzIzT0hHdHpIdGl2X2I0SGhuVHBfMlVQTzhibjc4eFBWRjk2Ynk3RHJB?oc=5","date":"2022-12-02","type":"trial","source":"IAVI","summary":"Scientists reveal encouraging findings in first-in-human clinical trial evaluating HIV vaccine approach - IAVI","headline":"Scientists reveal encouraging findings in first-in-human clinical trial evaluating HIV vaccine approach","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi9wFBVV95cUxNbHI2U290RmE1OW84QXg5TERBdmIwN3VYeUF1UU9lRjZXT0JpVHdMeVdaOTdubXRlUk54YXRzS3FCblB1TW1VTllwQnB2NUc2UjAwVUZBU0tUbzJXbUxvdUQxSmtEVnoyNk5vTDFXY19PMzRVM3F4N1VNNHdIeGFWempLdE9CblFlVlluOEJTM0NNY0pHZHYtb2FLTzRDMGFpSURjeEJ4NDdCS3I5ZVNsU2tTSHRBSktiNWRhcDhBOUhMOXJaSFlOQi0xUnlMUVZ3elY5dVVqWHNhT1VKVGVuMFN1czFfWEtxNERCUTdRdHl3eklqU1Rj?oc=5","date":"2021-07-14","type":"trial","source":"IAVI","summary":"Spanish pharmaceutical company Zendal and IAVI partner to advance the tuberculosis vaccine candidate MTBVAC into efficacy trials - IAVI","headline":"Spanish pharmaceutical company Zendal and IAVI partner to advance the tuberculosis vaccine candidate MTBVAC into efficac","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPQ1ZfWDRGRWgzeS11S2wwUjhrLU54WkZXWmpmc2g2WEllaFlVU1ZkbzVBM3dDeHhueC1XMENDalpWbEdVdDMxQkdNdW1aVjlKMGV6WTVKc04xUzdremRUQkdSdVBHdU45SmlzazY5Y3N0NVotNXh3ejh3SnZQZExRZ1V2TUpqeGkydzNXYlRJQVQyLVBpUTJzdDJzeGpqWXEzUlJzX1NneDlkSzBnenQ0Wnc3bFdnNi12aklRSEc2TjBvSGc?oc=5","date":"2019-03-27","type":"trial","source":"IAVI","summary":"IAVI Announces First-in-Human Clinical Trial of Native-like HIV Envelope Vaccine Candidate - IAVI","headline":"IAVI Announces First-in-Human Clinical Trial of Native-like HIV Envelope Vaccine Candidate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7gFBVV95cUxPQTdhZVpuZVRCa0ZxWFUwZ3ltZmNRaHhTVEdaRmdENEVXeDdLVmMzNUZLQkZuRGloZXJTODZoWEp3dTRYTmRzemNJRW9nLWJDNFJlQ1RYWGg4SHliZkpKRzdxNnBoeDRQd0VPSEZPWjluZ2k5a2FOY1owMVozZDM3ajB3ZS1zS3hzY0hidk9ETFBNc1hMM3dONW1scUxld2RjZ2lVN01kS3FCT0l5SDhySThvU2pXN3JpV1A3bmstNFhuR3FZUWpMN2ZUUE1wSE10bUFObDR2RE9fcDNhUXROek55QVNQb1FNUm1aNTh3?oc=5","date":"2018-10-22","type":"pipeline","source":"IAVI","summary":"IAVI and Serum Institute of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products for HIV - IAVI","headline":"IAVI and Serum Institute of India to Develop and Manufacture Globally Affordable and Accessible Antibody Products for HI","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":1,"phase_1":3},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}